Advancing Women’s Healthcare

Listening has long played a significant role in treating patients. Over a century ago, Sigmund Freud, in a revolutionary innovation, showed that in order to understand and effectively treat patients, a doctor had to listen to them.

Our commitment to listening serves us well in our goal of advancing women’s healthcare. Too often, women suffer in silence. We are engaged in activities ranging from the development and commercialization of new medications to patient advocacy with the goal of helping women feel more comfortable speaking up and getting the help they need.

Our initial therapeutic focus is the treatment of moderate to severe painful intercourse due to menopause, a symptom of vulvar and vaginal atrophy (VVA), a common condition experienced by millions of women after menopause. In 2013, we introduced Osphena® (ospemifene tablets), an oral non-estrogen prescription medication, which was recognized by the Cleveland Clinic in 2013 as one of the top 100 women’s health highlights of the year, and is included in guidelines issued by both the American College of Obstetricians and Gynecologists (ACOG) and the North American Menopause Society (NAMS). Click here for Full Prescribing Information including Boxed WARNING1, and Patient Information.

At Shionogi Inc., we firmly believe no medical treatment for painful intercourse after menopause is complete without candid and open dialogue between women and their healthcare providers. Accordingly, we support a range of professional and consumer education programs to help facilitate these discussions.

  1. Taking estrogen alone or Osphena may increase your chance for getting cancer of the lining of the uterus, strokes, and blood clots. Vaginal bleeding after menopause may be a warning sign of cancer of the lining of the uterus. Your healthcare provider should check any unusual vaginal bleeding to find out the cause, so tell them right away if this happens while you are using Osphena.